M S Sudheesh
Overview
Explore the profile of M S Sudheesh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sah S, Ajay S, Donadkar A, Kamath A, Devan A, Soman R, et al.
Int J Pharm
. 2025 Jan;
671:125261.
PMID: 39855283
Kaempferol (KP), a GRAS-certified phytomolecule enrolled in Phase I trials, is reported with various biological effects including anticancer activity. However, its poor pharmacokinetic profile limits the translational utility. Studies indicate...
2.
Nair A, Briget Kuriakose B, Biju A, Surendran S, Sudheesh M, Lakshmi P
J Ayurveda Integr Med
. 2025 Jan;
16(1):101041.
PMID: 39799838
Multi-targeted drug therapy has received substantial attention for the treatment of diseases of multi-factorial origin, including neurodegenerative and autoimmune diseases. It seems reasonable to argue that the complex pathology of...
3.
Agrawal N, Kumar G, Pandey S, Yadav S, Kumar M, Sudheesh M, et al.
Curr Pharm Des
. 2024 Dec;
PMID: 39694966
Type 1 Diabetes is an autoimmune disease characterized by the destruction of insulin-producing pancreatic β-cells, leading to hyperglycemia and various complications. Despite insulin replacement therapy, there is a need for...
4.
Nair A, Benny S, Aneesh T, Sudheesh M, Lakshmi P
J Ethnopharmacol
. 2024 Nov;
338(Pt 1):119024.
PMID: 39489356
Ethnopharmacological Relevance: Multi-targeted drug therapy has received substantial attention for the treatment of diseases of multifactorial origin, such as neurodegenerative diseases. Manasamitra vatakam (MMV) is a traditional Ayurvedic formulation used...
5.
Nambiar N, Gaur S, Ramachandran G, Pandey R, M S, Nath L, et al.
J Liposome Res
. 2024 Feb;
34(4):658-670.
PMID: 38343137
Liposomes have gained prominence as nanocarriers in drug delivery, and the number of products in the market is increasing steadily, particularly in cancer therapeutics. Remote loading of drugs in liposomes...
6.
Chacko I, Ramachandran G, Sudheesh M
Drug Deliv Transl Res
. 2023 Nov;
14(4):841-857.
PMID: 37957474
Age-appropriateness of a formulation is the ability to deliver variable but accurate doses to the paediatric population in a safe and acceptable manner to improve medical adherence and reduce medication...
7.
Krishna S, Sudheesh M, Viswanad V
J Liposome Res
. 2023 Apr;
33(4):410-424.
PMID: 37074963
High local delivery of anti-infectives to the lungs is required for activity against infections of the lungs. The present pandemic has highlighted the potential of pulmonary delivery of anti-infective agents...
8.
Ramkar S, Kaurav M, Sudheesh M, Pandey R
Drug Dev Ind Pharm
. 2023 Feb;
49(1):52-61.
PMID: 36803490
Long-term treatment with finasteride (FIN) for androgenic alopecia is restricted due to its systemic side effects. To address this problem, DMSO-modified liposomes were prepared in the present study to improve...
9.
Boinapalli Y, Pandey R, Chauhan A, Sudheesh M
Int J Pharm
. 2023 Jan;
632:122579.
PMID: 36603671
Cell uptake study is a routine experiment used as a surrogate to predict in vivo response in cancer nanomedicine research. Cell culture conditions should be designed in such a way...
10.
Sudheesh M, Pavithran K, M S
Nanoscale Adv
. 2022 Sep;
4(3):634-653.
PMID: 36131837
The field of cancer nanomedicine has been fueled by the expectation of mitigating the inefficiencies and life-threatening side effects of conventional chemotherapy. Nanomedicine proposes to utilize the unique nanoscale properties...